



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 18-12-2009

Mr. Munir Ahmed,
Director (Admn.),
IPO-Pakistan,
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 26-11-2009 TO BE PUBLISHED 21-12-2009
IN THE GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No. 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 99215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

23-11-2009

1027/2009	Boehringer Ingelheim International GmbH, Germany (Priority 24-11-2008 Europe)	“New compounds”
1028/2009	Eli Lilly and Company, USA (Priority 21-11-2008 USA)	“C-met therapeutic antibodies”
1029/2009	Abbott Laboratories, USA (Priority 28-11-2008 USA)	Stable antibody compositions and methods for stabilizing same
1030/2009	Eli Lilly and Company, USA (Priority 12-09-2003 USA) <u>Divisional</u>	“Pharmaceutically acceptable salt of a substituted 2-carboxylamino-6-piperidinaminopyridine”

24-11-2009

1031/2009	Astrazeneca AB., Sweden (Priority 25-11-2008 USA)	“Spirocyclobutyl piperidine derivatives”
1032/2009	Wajihullah Bukhari, Islamabad, Pakistan	“High-sweet coated crystalline cane orbeet sugar”
1033/2009	Eli Lilly and Company, USA (Priority 05-12-2008 USA)	“Anti-ferroportin 1 monoclonal antibodies and uses thereof”
1034/2009	Basf se, Germany (Priority 25-11-2008 USA)	“Multipurpose ant bait”
1035/2009	RWE Power Aktiengesellschaft, Germany (Priority 24-11-2008 Europe)	“Vorrichtung zur streuung von schuttgut”

1036/2009	RWE Power Aktiengesellschaft, Germany (Priority 24-11-2008 Europe)	“Verfahren zum erzeugen von prozessdampf”
1037/2009	RWE Power Aktiengesellschaft, Germany (Priority 24-11-2008 Europe)	“Indirekt beheizter wirbelschichttrockner”
1038/2009	RWE Power Aktiengesellschaft, Germany (Priority 24-11-2008 Europe)	“Verfahren zur aufbereitung von braunkohle”
1039/2009	Nokia Corporation, Finland (Priority 13-12-2006 USA) <u>Divisional</u>	“System and method for managing network connectivity disruptions in a multi-homed upnp device”
1040/2009	Dr. Sabira Begum, Dr. Syed Nawazish Ali, Prof. Dr. Bina S. Siddiqui, International Center for Chemical and Biological Sciences H.E.J Research Institute of Chemistry, University of Karachi, Pakistan	“A process for the synthesis of new anti-tuberculosis agents”
<u>25-11-2009</u>		
1041/2009	Retractable Technologies Inc., USA Thomas j. Shaw., USA (Priority 25-11-2008 USA)	“Glass syringe with retractable needle”
1042/2009	Crystal lagoons Corporation LLC., USA (Priority 24-12-2008 Chilean)	“Efficient filtration process of water in a tank for recreational and ornamental uses, where the filtration is performed over a small volume of water and not over the totality of the water from the tank”
1043/2009	Dr. Mehjabeen, Dr. Shakeel Ahmad, Dr. Sagheer Ahmad, Noor jehan, Department of Pharmacology, Faculty of Pharmacy, Federal Urdu	“A herbal composition for treating diabetes mellitus”

	University of Arts, Sciences & Technology, Karachi, Pakistan	
1044/2009	Dr. Mehjabeen, Dr. Shakeel Ahmad, Dr. Sagheer Ahmad., Faculty of Pharmacy, Federal Urdu University of Arts, Sciences & Technology, Karachi, Pakistan	“Herbal composition for hormone imbalance treatment during menopause”
1045/2009	Dr. Mehjabeen. Dr. Shakeel ahmad. Dr. Sagheer ahmad. Department of Pharmacology, Faculty of Pharmacy, Federal Urdu University of Arts, Sciences & Technology, Karachi, Pakistan	“Herbal composition for treating eczema”
1046/2009	Takeda Pharmaceutical Company, Limited, Japan (Priority 02-12-2008 Japan)	“Heterocyclic compound and use thereof”
1047/2009	Sanofi-Aventis, France. (Priority 28-11-2008 Europe)	“Antitumor combinations containing antibodies recognizing specifically CD-38 and melphalan”
1048/2009	Sanofi-Aventis, France (Priority 28-11-2008 Europe)	“Antitumor combinations containing antibodies recognizing specifically CD-38 and cyclophosphamide”
1049/2009	Sanofi-Aventis, France (Priority 28-11-2008 Europe)	“Antitumor combinations containing antibodies recognizing specifically CD-38 and cytarabine”
1050/2009	Sanofi-Aventis, France (Priority 28-11-2008 Europe)	“Antitumor combinations containing antibodies recognizing specifically CD-38 and vincristine”
1051/2009	Abbott Laboratories, USA (Priority 26-11-2008 USA)	“Novel substituted octahydrocyclopenta[c]pyrrol-4-amines as calcium channel blockers”

1052/2009	Otsuka Pharmaceutical co. Limited, Japan	“Fermented product containing equol producing microorganism by which equol production ability is maintained and production process thereof”
<u>26-11-2009</u>		
1053/2009	Sanofi-Aventis, France (Priority 01-12-2008 France)	“6-cycloamino-3-(1H-pyrrolo[2,3- b]pyridine-4-yl)imidazo[1,2- b]pyridazine derivatives preparation, thereof and therapeutic use thereof”
1054/2009	Targocept Inc., USA (Priority 01-12-2008 USA)	“Synthesis and novel salt forms of ®-3-((E)-2-(pyrrolidin-3-yl)vinyl)- 5-(tetrahydropyran-4- yloxy)pyridine”
1055/2009	Sanofi-Aventis, France (Priority 24-03-2009 France)	“9H-pyrrolo[2,3-b: 5,4-c']dipyridine azacarboline derivatives, preparation and therapeutic use thereof”
1056/2009	Celanese International Corporation, USA	“Production of vinyl acetate from acetic acid via ethylene”

Wherein R¹ is hydrogen, C₁₋₆ alkyl or C₂₋₆ alkenyl wherein said alkyl and alkenyl groups are optionally substituted with one to six halo, C₃₋₆ cycloalkyl, -SR⁹, -SR¹², -SOR⁹, -SOR¹², SO₂R⁹, SO₂R¹², -SO₂CH(R¹²)(R¹¹), -OR¹², -OR⁹, -N(R¹²)₂, aryl, heteroaryl or heterocycly.

R³ is hydrogen C₁₋₆alkyl or C₂₋₆ alkenyl

R⁴ is hydrogen C₁₋₆ alkyl or C₂₋₆ alkenyl

R⁵ is selected from hydrogen or C₁₋₆ alkyl substituted with 1-6 halo;

R⁶ is aryl, heteroaryl, C₁₋₆ haloalkyl, arylalkyl or heteroarylalkyl

R⁷ is hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkyloxy, halo, nitro, cyano, aryl, heteroaryl, C₃₋₈ cycloalkyl, heterocyclyl, -C(O)OR¹⁰

R⁸ is hydrogen or C₁₋₆ alkyl

R⁹ is selected from the group consisting of hydrogen, aryl aryl(C₁₋₄)alkyl, heteroaryl, heteroaryl(C₁₋₄)alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl(C₁₋₄)alkyl, and heterocyclyl(C₁₋₄)alkyl.

R¹⁰ is hydrogen or C₁₋₆ alkyl

R¹¹ is hydrogen or C₁₋₆ alkyl;

R¹² is hydrogen or C₁₋₆ alkyl, which is optionally substituted with one, two or three substituents independently selected from halo, alkoxy, -NR¹⁰ or -SR¹⁰

“Container for containment and transport of objects”

179/2005 Deutsche Post AG.,
Germany

B65D 47/26

140367

A container including at least three sidewalls with corners therebetween defining an internal space for storage of at least one item the sidewalls having an open base and an open top. The sidewalls are foldable about the corners for ease of storage, There is also a cover for the internal space, and a pallet onto which the sidewalls can be placed. The sidewalls have at least one perforated line to enable the height of the sidewalls to be varied.

203/2005

SmithKline Beecham plc.,
United Kingdom

“A pharmaceutical composition for moulded component comprising poly(Meth)acrylate copolymer”

A61K 9/48

140368

The present invention is directed to novel pharmaceutically acceptable polymeric composition suitable for injection molding of single or multi-component pharmaceutical dosage form comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form by a weld between parts of the assembled dosage form.

440/2005

Institut Francais Du Petrole,
France
ENI S.p.A.,
Italy

“A process for the production of liquid hydrocarbon by the fischer tropesch process with improved regulation”

C10G 2/00

140369

A process for the production of liquid hydrocarbon by the Fischer-Tropsch process comprises a step a) for generating a synthesis gas, a step b) for Fischer-Tropsch synthesis, a step c) for condensing the gaseous effluent obtained during step b), a step d) for separating the effluent condensed during step c) to obtain a gaseous effluent enriched in carbon monoxide and hydrogen, and a step e) for recycling at least a portion of the enriched gaseous effluent obtained during step d) to the Fischer-Tropsch synthesis step b), characterized in that:

1) two molar ratio of concentrations, A1 and A2, are determined between the hydrogen and the carbon monoxide (H_2/CO), A1 being the value of said ratio in the supply to the synthesis step b), and A2 being the value of said ratio in any one of the gaseous effluents

1198/2006 Daniel Serrano Gil,
Spain

obtained during steps b)toe);
2) comparing ratios A1 and A2; and
3) adjusting the concentrations of hydrogen
and/or carbon monoxide in the synthesis gas
to keep the difference between the two ratios
A1 and A2 substantially constant.
“A immune liposome composition”

A61K 9/127

140370

A composition designed to be administered to a mammal or to a human being for the purpose of destroying damaged and pathogenic cells and which includes empty liposomes, structural protein elements and specific binding elements selected depending on the pathogenic micro-organism or cell to be destroyed, in such a way that on being administered to the patient the composition acts as an effective effecting agent which interacts with the membrane of the target cell or with the membrane of the micro-organism to create drainage outlets that eliminate the intracellular content into the extracellular medium.

1021/2007 CompAir UK Limited,
United Kingdom

“A modular compressor comprising three separate adjoining sections with improved cooling and noise level”

F04D 17/12, F04D 29/66

140371

The invention relates to improvements in compressor units, and in particular to a modular compressor unit which has separate sections for the compressor, the controls and the air intake. The modular compressor unit comprises three separate adjoining sections, being an intake section, a compression section and a control section. The intake section comprises air intake means which provide an inlet for ambient air to be compressed and for cooling the compressor motor and comprises filters to filter air

entering the intake means, noise attenuation means provided in the air intake means, and means for directing air to components in the compression section. The compression section comprises a compressor, a motor arranged to drive the compressor and all components within the unit required to cool compressed air, the motor and to remove heat from the compression section. The control section houses all the control means for operating the compressor unit.

1198/2007 Kawasaki Plant Systems
Kabushiki Kaisha,
Japan

“A power generation system using waste heat of a cement calcinations plant”

F01K 27/02, F01K 25/10

140372

A waste heat power generation system of a cement calcination plant includes: an AQC boiler having an economizer, an evaporator and a superheater; and a PH boiler having a first evaporator and a superheater. The PH boiler, in addition to the evaporator and the superheater, has a second evaporator on a PH exhaust gas exit side, and a returned hot water from a flasher is introduced into the second evaporator via a steam drum. A hot water heated by the second evaporator is introduced into the steam drum, and a steam from the steam drum is introduced into the low-pressure stage of a steam turbine.


1535/2007 Merck & Co. Inc.,
USA

“A pharmaceutically acceptable salt or solvate of a substituted pyridine-3-carboxylic acid compound”

CO7D 271/06, CO7C 233/46

140373

The present invention encompasses a pharmaceutically acceptable salt or solvate of a compound of Formula I:



I

that is useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical composition and method of use are also included.


666/2008 Bayer CropScience SA.,
France

“Pesticidal composition comprising a strigolactone derivative and an insecticide compound”

A01N 43/08

140374

A composition comprising at least a strigolactone compound (a) of general formula:



and an insecticide compound (b) in a (a)/(b) weight ratio of from 1/1 to 1/10¹³; A composition further comprising an additional fungicidal compound; a method for preventively or curatively combating the pests and diseases of crops and increasing their yield by using this composition.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 99215488